| scholarly article | Q13442814 |
| P50 | author | Uma V Mahajan | Q92914483 |
| Chad T Blackshear | Q92914485 | ||
| Timothy J. Hohman | Q48930313 | ||
| Cristina Legido-Quigley | Q52448581 | ||
| Anup Mammen Oommen | Q57412751 | ||
| P2093 | author name string | Sudhir Varma | |
| Juan C Troncoso | |||
| Yang An | |||
| Vijay R Varma | |||
| Madhav Thambisetty | |||
| Richard O'Brien | |||
| Michael E Griswold | |||
| Olga Pletnikova | |||
| P2860 | cites work | Astrocyte Biomarkers in Alzheimer's Disease | Q90903157 |
| Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects | Q91546700 | ||
| Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far | Q92080667 | ||
| Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data | Q24537656 | ||
| Is L-methionine a trigger factor for Alzheimer's-like neurodegeneration?: Changes in Aβ oligomers, tau phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice | Q27301311 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| Methionine restriction and life-span control | Q28083458 | ||
| Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography | Q28305137 | ||
| Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease | Q28544957 | ||
| Reduced MTHFD1 activity in male mice perturbs folate- and choline-dependent one-carbon metabolism as well as transsulfuration | Q28593558 | ||
| Isoform-level brain expression profiling of the spermidine/spermine N1-Acetyltransferase1 (SAT1) gene in major depression and suicide | Q28604131 | ||
| Power failure: why small sample size undermines the reliability of neuroscience | Q29547474 | ||
| The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease | Q29614948 | ||
| limma powers differential expression analyses for RNA-sequencing and microarray studies | Q29617988 | ||
| Is the urea cycle involved in Alzheimer's disease? | Q30433662 | ||
| Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis | Q30996805 | ||
| Astrocytes convert network excitation to tonic inhibition of neurons | Q31051117 | ||
| N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction | Q31997000 | ||
| N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology | Q33271816 | ||
| A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study | Q33575018 | ||
| Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes | Q33772805 | ||
| Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal | Q34025609 | ||
| Alzheimer's disease: cell-specific pathology isolates the hippocampal formation | Q34261572 | ||
| Quantitative Metabolome Analysis Using Capillary Electrophoresis Mass Spectrometry | Q34272743 | ||
| Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA) | Q34298372 | ||
| S-Adenosylmethionine and methylation | Q34382111 | ||
| Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. | Q34587455 | ||
| Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism in Young Women Consuming Choline Intakes Meeting Current Recommendations. | Q34680631 | ||
| Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease | Q34734276 | ||
| Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis | Q35371270 | ||
| Overview of the brain polyamine-stress-response: regulation, development, and modulation by lithium and role in cell survival | Q35545548 | ||
| Evolutionary conserved longevity genes and human cognitive abilities in elderly cohorts | Q35768402 | ||
| Alzheimer's disease and acetylcholine receptors. | Q35801150 | ||
| Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study | Q36316280 | ||
| Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID) | Q36768001 | ||
| Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder | Q36869854 | ||
| A post-mortem study of the cholinergic and GABA systems in senile dementia | Q48938665 | ||
| Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome | Q48939802 | ||
| Altered Expression of Urea Cycle Enzymes in Amyloid-β Protein Precursor Overexpressing PC12 Cells and in Sporadic Alzheimer's Disease Brain | Q50034542 | ||
| Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing? | Q50643354 | ||
| Genome instability in Alzheimer disease. | Q53116855 | ||
| Effect of a clinical stroke on the risk of dementia in a prospective cohort. | Q53282022 | ||
| Altered arginine metabolism in Alzheimer's disease brains. | Q53463642 | ||
| Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. | Q54996405 | ||
| Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate/aspartate shuttle | Q72808469 | ||
| Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry | Q73601388 | ||
| Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry | Q84064359 | ||
| Metabolomics Platform with Capillary Electrophoresis Coupled with High-Resolution Mass Spectrometry for Plasma Analysis | Q89993505 | ||
| Unsupervised excitation: GABAergic dysfunctions in Alzheimer's disease | Q90022236 | ||
| Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats | Q90700650 | ||
| Metabolic profiling of Alzheimer's disease brains | Q37072582 | ||
| The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future | Q37216751 | ||
| Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease | Q37219754 | ||
| Effect of infarcts on dementia in the Baltimore longitudinal study of aging | Q37221901 | ||
| Impaired glutathione synthesis in neurodegeneration | Q37291406 | ||
| Memory performance is related to amyloid and tau pathology in the hippocampus | Q37445497 | ||
| Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond | Q37820231 | ||
| One-carbon metabolism and Alzheimer's disease: is it all a methylation matter? | Q37869578 | ||
| Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections | Q38014513 | ||
| Neurotoxicity of amyloid β-protein: synaptic and network dysfunction | Q38023860 | ||
| Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult | Q38161154 | ||
| The role of glia in stress: polyamines and brain disorders | Q38278661 | ||
| Molecular signatures of longevity: Insights from cross-species comparative studies. | Q38628486 | ||
| Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels | Q38648373 | ||
| Targets of polyamine dysregulation in major depression and suicide: Activity-dependent feedback, excitability, and neurotransmission. | Q38815980 | ||
| Functions of Polyamines in Mammals | Q38857007 | ||
| Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism. | Q38926696 | ||
| Targeting nuclear thymidylate biosynthesis | Q39017134 | ||
| Role of glutathione in the regulation of epigenetic mechanisms in disease | Q39433555 | ||
| The concept of "aldehyde load" in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line | Q40158684 | ||
| Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines | Q40274730 | ||
| Polyamine catabolism is enhanced after traumatic brain injury. | Q40473351 | ||
| Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-aminopropanal | Q40537240 | ||
| Endogenous ornithine in search for CNS functions and therapeutic applications | Q40796184 | ||
| Brain glutathione levels--a novel biomarker for mild cognitive impairment and Alzheimer's disease | Q40908046 | ||
| Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. | Q41107342 | ||
| The Cerebellum in Alzheimer's Disease | Q41523002 | ||
| How sample size influences research outcomes. | Q43108476 | ||
| Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry | Q44011338 | ||
| Alzheimer's disease: amino acid levels and brain metabolic status. | Q44142866 | ||
| Glutathione relates to neuropsychological functioning in mild cognitive impairment. | Q46730752 | ||
| Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. | Q47549112 | ||
| Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden | Q47607239 | ||
| Choline, the brain and neurodegeneration: insights from epigenetics | Q47617681 | ||
| Evidence for brain glucose dysregulation in Alzheimer's disease | Q47620628 | ||
| Metabolic profile alterations in the postmortem brains of patients with schizophrenia using capillary electrophoresis-mass spectrometry | Q47876247 | ||
| Spermidine in health and disease. | Q48163525 | ||
| Choline and its metabolites are differently associated with cardiometabolic risk factors, history of cardiovascular disease, and MRI-documented cerebrovascular disease in older adults. | Q48239148 | ||
| GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. | Q48296529 | ||
| Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease | Q48355200 | ||
| Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease | Q48386714 | ||
| Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition | Q48529489 | ||
| A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients | Q48694864 | ||
| A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease | Q48712776 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 1 | |
| P921 | main subject | metabolic network | Q2263094 |
| P304 | page(s) | e1003012 | |
| P577 | publication date | 2020-01-24 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study | |
| P478 | volume | 17 |
| Q89762134 | Blood Metabolite Signature of Metabolic Syndrome Implicates Alterations in Amino Acid Metabolism: Findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS) |
| Q99243079 | CE-MS for metabolomics: Developments and applications in the period 2018-2020 |
Search more.